Palatin Technologies (PTN) |
|
0.393 0.002 (0.49%)
|
01-21 17:32 |
|
Open: |
0.39 |
Pre. Close: |
0.3911 |
|
High:
|
0.4299 |
Low:
|
0.39 |
|
Volume:
|
2,204,214 |
Market Cap:
|
91M |
|
|
|
|
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.43 - 0.433 |
0.433 - 0.436 |
|
Low:
|
0.385 - 0.388 |
0.388 - 0.39 |
|
Close:
|
0.386 - 0.391 |
0.391 - 0.394 |
|
Technical analysis |
as of: 2022-01-21 4:29:38 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.59 One year: 0.67 |
| Support: |
Support1: 0.39 Support2: 0.32 |
| Resistance: |
Resistance1: 0.50 Resistance2: 0.57 |
| Pivot: |
0.45  |
| Moving Average: |
MA(5): 0.40 MA(20): 0.47
MA(100): 0.47 MA(250): 0.57 |
| MACD: |
MACD(12,26): -0.03 Signal(9): -0.02 |
| Stochastic oscillator: |
%K(14,3): 4.55 %D(3): 4.78  |
| RSI: |
RSI(14): 32.47 |
| 52-week: |
High: 1.30 Low: 0.33 Change(%): -55.3 |
| Average Vol(K): |
3-Month: 11481 10-Days: 1552 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.PTN has closed above bottom band by 17.1%. Bollinger Bands are 32.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 21 Jan 2022
Palatin: Pre-clinical Data Show Positive Effects Of Melanocortins For Ulcerative Colitis - Nasdaq
Sun, 02 Jan 2022
Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out - Kilgore News Herald
Tue, 28 Dec 2021
Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease - PRNewswire
Thu, 23 Dec 2021
Is Palatin Technologies, Inc. (PTN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Mon, 06 Dec 2021
Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Mon, 29 Nov 2021
Biofrontera, Palatin surge amid social media chatter - Seeking Alpha
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
229 |
| Shares Float (M) |
226 |
|
% Held by Insiders
|
3.33 |
|
% Held by Institutions
|
22.79 |
|
Shares Short (K)
|
10,060 |
|
Shares Short P. Month (K)
|
10,500 |
Stock Financials |
|
EPS
|
-0.100 |
|
EPS Est This Year
|
-0.350 |
|
EPS Est Next Year
|
-0.060 |
|
Book Value (p.s.)
|
0.350 |
|
Profit Margin
|
|
|
Operating Margin
|
-20007.61 |
|
Return on Assets (ttm)
|
-15.6 |
|
Return on Equity (ttm)
|
-24.8 |
|
Qtrly Rev. Growth
|
-100.0 |
|
Gross Profit (p.s.)
|
-0.060 |
|
Sales Per Share
|
0.001 |
|
EBITDA (p.s.)
|
-0.103 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
41 |
|
Levered Free Cash Flow (M)
|
48 |
Stock Valuations |
|
PE Ratio
|
-3.93 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.12 |
|
Price to Sales
|
763.62 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
